Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
1. Evogliptin 5mg Group: Administration with Evogliptin 5mg and Placebo for 24weeks 2. Pioglitazone 15mg Group: Administration with Pioglitazone 15mg and Placebo for 24weeks
Age
19 - 70 years
Sex
ALL
Healthy Volunteers
No
Samsung Medical Center
Changwon, South Korea
Soonchunhyang University Hospital
Cheonan, South Korea
Keimyung Dongsan University Medical Center
Daegu, South Korea
Hanyang University Guri Hospital
Guri-si, South Korea
Catholic University of Seoul ST.Mary's Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Start Date
April 12, 2019
Primary Completion Date
July 2, 2020
Completion Date
July 2, 2020
Last Updated
April 29, 2021
51
ACTUAL participants
Evogliptin
DRUG
Pioglitazone
DRUG
Lead Sponsor
Dong-A ST Co., Ltd.
NCT06819917
NCT07221227
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06218589